Traditional photodynamic therapy (PDT) is a method of using a visible light with a certain wavelength to irradiate photofrin, converting O2 into 1O2 by energy conversion for treatment of diseases, and many photofrin kinds of new drugs have been marketed and widely used in clinic. The present invention relates to therapeutical mechanism totally different from PDT, in which the specific affinity of photofrin to focus, such as tumors, vascular plaques and skin diseases, is utilized, and a certain means is used to activate photofrin in the focus, catalyze the decomposition reaction of H2O2 to generate 1O2 in the focus, 1O2 further induces apoptosis and necrosis of cells with pathological changes, the purpose of treating tumors, vascular plaques and skin diseases is achieved, and cosmetic effects on skin are prompted. A series of new drugs obtained via the screening and studying of the present invention are used for Chemodynamic Therapy (CDT), or for Radiochemodynamic Therapy (RCDT) carried out via radioactive rays. The action mechanism of the drugs is as follows:In the formula, photofrin can be endogenous (e.g., 5-ALA synthetic endogenous porphyrin), or exogenous； H2O2 can be exogenous, or can be endogenous H2O2 generated by means of hydrogen peroxidase inhibitor； the activation of photofrin is carried out by specific protein binding or by electron beam, x-ray, r-ray, or other means. In comparison with traditional photodynamic therapy (PDT), CDT and RCDT have advantages in: no need for light source； no need for oxygen； able to be quantitated； no need for intervention means； good therapeutical effects； simpler operation； capable of being repeated therapy； easy for popularization and application. The present invention relates to a series of new drugs useful in CDT and RCDT. The series of new drugs refer to chemical series capable of catalyzing the decomposition of H2O2 to generate singlet oxygen (1O2). They have no notable side effects on human body, at same time have a
